Howard Broder, MD
Interventional Cardiology · Henderson, NVNPI 1336361500
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 85.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $71,345 and has fallen 97.9% since, to $1,511 in 2025. Among interventional cardiology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $348.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$144K
- Abbott$11K
- Edwards Lifesciences$4K
- Abiomed$3K
- Shockwave Medical, Inc$2K
- Terumo Medical Corporation$1K
- plus $3K from 18 others
What the payments were for
- Consulting fees$7,1004%
- Speaking & faculty fees$98,08158%
- Travel & lodging$37,74422%
- Food & beverage$25,25615%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 278 | $144,161 |
| Abbott | 43 | $10,717 |
| Edwards Lifesciences | 17 | $3,977 |
| Abiomed | 58 | $3,435 |
| Shockwave Medical, Inc | 29 | $2,086 |
| Terumo Medical Corporation | 6 | $1,126 |
| Philips North America LLC | 13 | $429 |
| W. L. Gore & Associates, Inc. | 2 | $305 |
| Heartflow, Inc. | 3 | $287 |
| Cvrx, Inc. | 2 | $246 |
| Surmodics, Inc. | 2 | $230 |
| AstraZeneca | 2 | $172 |
| Teleflex LLC | 3 | $152 |
| Penumbra, Inc. | 1 | $143 |
| Scpharmaceuticals Inc. | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Boston Scientific | 2 | $114 |
| Johnson & Johnson | 7 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $100 |
| Amgen | 4 | $57 |
| Bard Peripheral Vascular, Inc. | 1 | $45 |
| Novartis | 1 | $24 |
| Cardiovascular Systems Inc. | 3 | $24 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$108,796
- COREVALVE EVOLUT R$27,859
- AMPLATZER AMULET$6,851
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,350
- Mitra Clip system$1,902
- Impella$1,471
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,059
- CARDIOMEMS$637
- Optitorque$362
- Heartrail$362
- Glidesheath$362
- Vascular Lithotripsy$354
- HawkOne$272
- MitraClip$262
- Barostim Neo System$246
- TR Band$245
- FFRct$197
- PORTICO$191
- AZURE XT DR MRI SURESCAN$173
How this compares
$168,203 in reported general payments places this provider in the 95th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $126,317 |
| XareltoRivaroxaban | 32 | $33,344 |
| Repatha SureclickEvolocumab | 27 | $26,251 |
| EntrestoSacubitril/Valsartan | 16 | $18,650 |
| ClopidogrelClopidogrel Bisulfate | 120 | $1,514 |
| Atorvastatin Calcium | 127 | $1,148 |
| Rosuvastatin Calcium | 70 | $888 |
| Metoprolol Succinate | 74 | $832 |
| Nebivolol Hcl | 13 | $767 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $417 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $409 |
| Losartan Potassium | 44 | $397 |
| Ezetimibe | 16 | $331 |
| Metoprolol Tartrate | 32 | $300 |
| Amlodipine Besylate | 48 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $105 | $33,34432 claims |
| NovartisEntresto | $24 | $18,65016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Henderson
- Jeffrey LevismanHenderson$226K
- Karthiek NaralaHenderson$44K
- Dane JeficHenderson$17K
- Nicholas KalayehHenderson$11K
- Cam ChojiHenderson$8K
- Cres MirandaLas Vegas$660K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Neville MistryLas Vegas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.